Exelixis Ownership
| EXEL Stock | USD 34.83 0.18 0.52% |
Shares in Circulation | First Issued 1999-12-31 | Previous Quarter 294 M | Current Value 291.5 M | Avarage Shares Outstanding 176.9 M | Quarterly Volatility 107.2 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Exelixis |
Exelixis Stock Ownership Analysis
About 89.0% of the company shares are held by institutions such as insurance companies. The book value of Exelixis was currently reported as 7.96. The company has Price/Earnings To Growth (PEG) ratio of 2.5. Exelixis had not issued any dividends in recent years. Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California. Exelixis operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 954 people. To learn more about Exelixis call Michael Morrissey at 650 837 7000 or check out https://www.exelixis.com.Besides selling stocks to institutional investors, Exelixis also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Exelixis' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Exelixis' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Exelixis Quarterly Liabilities And Stockholders Equity |
|
Exelixis Insider Trades History
Only 1.6% of Exelixis are currently held by insiders. Unlike Exelixis' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Exelixis' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Exelixis' insider trades
Exelixis Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Exelixis is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Exelixis backward and forwards among themselves. Exelixis' institutional investor refers to the entity that pools money to purchase Exelixis' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Nuveen Asset Management, Llc | 2024-06-30 | 4.1 M | Stephens Inv Mgmt Group Llc | 2024-09-30 | 3.8 M | Aqr Capital Management Llc | 2024-06-30 | 3.3 M | Charles Schwab Investment Management Inc | 2024-09-30 | 3.3 M | Norges Bank | 2024-06-30 | 2.8 M | Bank Of New York Mellon Corp | 2024-06-30 | 2.7 M | First Trust Advisors L.p. | 2024-06-30 | 2.6 M | Jacobs Levy Equity Management, Inc. | 2024-06-30 | 2.5 M | Fmr Inc | 2024-09-30 | 2.5 M | Blackrock Inc | 2024-06-30 | 33.5 M | Vanguard Group Inc | 2024-09-30 | 29.3 M |
Exelixis Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Exelixis insiders, such as employees or executives, is commonly permitted as long as it does not rely on Exelixis' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Exelixis insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Exelixis Outstanding Bonds
Exelixis issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Exelixis uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Exelixis bonds can be classified according to their maturity, which is the date when Exelixis has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| EXELON P 495 Corp BondUS30161NAQ43 | View | |
| EXELON P 395 Corp BondUS30161NAN12 | View | |
| EXELON P 34 Corp BondUS30161NAU54 | View | |
| EXELON P 51 Corp BondUS30161NAS09 | View | |
| EXC 335 15 MAR 32 Corp BondUS30161NBE04 | View | |
| EXELON PORATION Corp BondUS30161NAY76 | View |
Exelixis Corporate Filings
F4 | 19th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 29th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Exelixis. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exelixis. If investors know Exelixis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exelixis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 121.699 | Earnings Share 1.55 | Revenue Per Share 7.032 | Quarterly Revenue Growth 0.143 | Return On Assets 0.1281 |
The market value of Exelixis is measured differently than its book value, which is the value of Exelixis that is recorded on the company's balance sheet. Investors also form their own opinion of Exelixis' value that differs from its market value or its book value, called intrinsic value, which is Exelixis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exelixis' market value can be influenced by many factors that don't directly affect Exelixis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exelixis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Exelixis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exelixis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.